I-MAB (IMAB) NonCurrent Deferred Liabilities : $37.37 Mil (As of Jun. 2023)

View and export this data going back to 2020. Start your Free Trial

What is I-MAB NonCurrent Deferred Liabilities?

Non-Current Deferred Liabilities represents the non-current portion of obligations, which is a liability that usually would have been paid but is now pas due.

I-MAB's non-current deferred liabilities for the quarter that ended in Jun. 2023 was $37.37 Mil.

I-MAB NonCurrent Deferred Liabilities Historical Data

The historical data trend for I-MAB's NonCurrent Deferred Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

I-MAB NonCurrent Deferred Liabilities Chart

I-MAB Annual Data

Trend

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

NonCurrent Deferred Liabilities

Get a 7-Day Free Trial

0.56

1.37

37.51

40.86

40.91

I-MAB Semi-Annual Data
	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
NonCurrent Deferred Liabilities	Get a 7-Day Free Trial								37.51	37.93	40.86	37.37	40.91

I-MAB NonCurrent Deferred Liabilities Related Terms

Thank you for viewing the detailed overview of I-MAB's NonCurrent Deferred Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.

I-MAB (IMAB) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » I-MAB (NAS:IMAB) » Definitions » NonCurrent Deferred Liabilities

Comparable Companies

Traded in Other Exchanges

0VY:Germany

Address

555 West Haiyang Road, 55th Floor, New Bund Center, Pudong District, Shanghai, CHN, 200124

Website

https://www.i-mabbiopharma.com

I-Mab Biopharma is a clinical-stage biotech company in China that listed on Nasdaq in January 2020. Its first commercial drug will likely be eftansomatropin, a long-acting growth hormone that has a large market in China among pediatric patients with short stature, which we estimate will launch in 2024 or 2025. Other core assets include lemzoparlimab, a potential best-in-class CD47 inhibitor in phase 2 trials; uliledlimab, a potential best-in-class CD73 inhibitor in phase 2 trials; and felzartamab for the Chinese market, a CD38 inhibitor for multiple myeloma, which could have a phase 3 data readout in 2023.